The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...
Michael Yee has given his Buy rating due to a combination of factors including the recent positive developments regarding Biogen’s Alzheimer’s drug, Leqembi, in the European market. The European ...
EU drugs regulator recommends approval of Leqembi for early Alzheimer's, pending European Commission acceptance, for specific ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys ...
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
Hosted on MSN22h
European committee takes a second look at Alzheimer's drug and now says it should be approvedBiogen said Thursday that the drug, known in the U.S. as Leqembi, received a positive opinion from the European Medicines ...
Europe's medicines watchdog partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease ...
The article provides an overview of recent developments in the healthcare sector, including Novo Nordisk's phase-out of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback